Targeting GRB7/ERK/FOXM1 Signaling Pathway Impairs Aggressiveness of Ovarian Cancer Cells
Open accessThe DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
Ovarian cancer is a highly lethal disease with poor prognosis and especially in high-grade tumor. Emerging evidence has reported that aberrant upregulation and activation of GRB7, ERK as well as FOXM1 are closely associated with aggresivenesss of human cancers. However, the interplay between these factors in the pathogenesis of human cancers still remains unclear. In this study, we found that GRB7 (P<0.0001), ERK phosphorylation (P<0.0001) and FOXM1 (P = 0.001) were frequently increased and associated with high-grade tumors, as well as a high tendency in association with advanced stage ovarian cancer by immunohistochemical analysis. Intriguingly, the expressions of GRB7 (P<0.0001), ERK phosphorylation (P<0.001) and FOXM1 (P<0.001) showed a significant stepwise increase pattern along Grade 1 to Grade 3 ovarian cancers. Biochemical studies using western blot analysis demonstrated that enforced expression or knockdown of GRB7 showed GRB7 could elevate the levels of ERK phosphorylation and FOXM1, whereas enforced expression of FOXM1 could not alter levels of GRB7 and ERK phosphorylation. But inhibition of ERK signaling by U0126 or PD98059 could reduce the level of FOXM1 in GRB7-overexpressing ovarian cancer cells, suggesting that GRB7, ERK and FOXM1 are regulated orderly. Moreover, inhibition of ERK activity by U0126 or PD98059, or decreased FOXM1 expression by Thiostrepton significantly inhibited cell migration/invasion, tumor growth in vitro and in vivo. Collectively, our findings confer that targeting GRB7/ERK/FOXM1 signaling cascade may be a promising molecular therapeutic choice in combating ovarian cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“GRB7 targeting inhibits ovarian cancer tumor growth through the ERK inhibition [36].”
From Genome-wide CRISPR-cas9 knockout screening identifies GRB7 as a driver for MEK inhibitor resistance in KRAS mutant colon cancer (2022) · cites this paper as [36]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mebratu, Y., & Tesfaigzi, Y. (2009) · Cell Cycle · doi:10.4161/cc.8.8.8147 · Cited by 957 · cited 1×
“Constitutive activation of ERK signaling pathway has been involved in human cancer development [30,31,32].”
BackgroundGrading Ovarian Serous Carcinoma Using a Two-Tier System
Malpica, A., Deavers, M. T., Lu, K., Bodurka, D. C., Atkinson, E. N., Gershenson, D. M., & Silva, E. G. (2004) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200404000-00009 · Cited by 670 · cited 1×
“nuclei, a high mitotic index, more aggressiveness, poorly differentiated, less responsive to chemotherapy as well as low survival rate [4,5,6].”
BackgroundVang, R., Shih, I.-M., & Kurman, R. J. (2009) · Advances in Anatomic Pathology · doi:10.1097/pap.0b013e3181b4fffa · Cited by 562 · cited 3×
“Ovarian cancer is a heterogeneous tumor exhibiting a wide range of cytological, clinical and altered genetic features [3,4].”
BackgroundSteelman, L. S., Chappell, W. H., Abrams, S. L., Kempf, C. R., Long, J., Laidler, P., Mijatovic, S., Maksimovic-Ivanic, D., Stivala, F., Mazzarino, M. C., et al. (2011) · Aging · doi:10.18632/aging.100296 · Cited by 553 · cited 1×
“Constitutive activation of ERK signaling pathway has been involved in human cancer development [30,31,32].”
BackgroundTargeting the RAF–MEK–ERK pathway in cancer therapy
Montagut, C., & Settleman, J. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.01.022 · Cited by 468 · cited 2×
“Besides, constitutive activation of ERK has been implicated in a variety of tumorigenic behaviors such as cell proliferation, differentiation, metastasis, angiogenesis, and chemoresistance in human cancers [13,14,15,16].”
BackgroundTargeting the ERK signaling pathway in cancer therapy
Kohno, M., & Pouyssegur, J. (2006) · Annals of Medicine · doi:10.1080/07853890600551037 · Cited by 416 · cited 1×
“Besides, constitutive activation of ERK has been implicated in a variety of tumorigenic behaviors such as cell proliferation, differentiation, metastasis, angiogenesis, and chemoresistance in human cancers [13,14,15,16].”
BackgroundFOXM1: From cancer initiation to progression and treatment
Koo, C.-Y., Muir, K. W., & Lam, E. W.-F. (2012) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2011.09.004 · Cited by 406 · cited 1×
“On the other aspect, emerging evidences have found that the aberrant upregulation of FOXM1 transcription factor is involved in the pathogenesis of various human cancers [17,21,22,38,39].”
BackgroundFOXM1, a typical proliferation-associated transcription factor
Wierstra, I., & Alves, J. (2007) · bchm · doi:10.1515/bc.2007.159 · Cited by 313 · cited 1×
“In addition, Forkhead Box M1 (FOXM1) has been identified as an oncogenic transcription factor which is frequently upregulated in numerous human cancers [17,18,19].”
BackgroundFoxM1: A Master Regulator of Tumor Metastasis
Raychaudhuri, P., & Park, H. J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0640 · Cited by 308 · cited 3×
“In addition, Forkhead Box M1 (FOXM1) has been identified as an oncogenic transcription factor which is frequently upregulated in numerous human cancers [17,18,19].”
BackgroundOvarian Cancer Pathogenesis: A Model in Evolution
Karst, A. M., & Drapkin, R. (2010) · Journal of Oncology · doi:10.1155/2010/932371 · Cited by 298 · cited 1×
“Ovarian cancer is a heterogeneous tumor exhibiting a wide range of cytological, clinical and altered genetic features [3,4].”
Background
Research works printed but not linked: 1
- Koo CY, Muir KW, Lam EW (2012) FOXM1: From cancer initiation to progression and treatment. Biochim Biophys Acta 1819: 28– 37. 21978825 · DOI · Paper page
Cited by
FOXM1 (Forkhead box M1) in Tumorigenesis
(2013) · Advances in Cancer Research · doi:10.1016/b978-0-12-407190-2.00016-2 · Cited by 184
“In particular, the FOXM1 expression level increases with tumor grade or stage (Carr et al., 2012; Chan et al., 2008, 2012; Chen et al., 2013b; Chu et al., 2012; He et al., 2012; Janus et al., 2011; Jiang et al., 2011; Kalin et al., 2006; Laurendeau et al., 2010; Li et al., 2012a, 2013; Lin et…”
BackgroundThe Transcription Factor FOXM1 (Forkhead box M1)
(2013) · Advances in Cancer Research · doi:10.1016/b978-0-12-407173-5.00004-2 · Cited by 176
FOXM1 and Cancer: Faulty Cellular Signaling Derails Homeostasis
Kalathil, D., John, S., & Nair, A. S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.626836 · Cited by 168
FoxM1: Repurposing an oncogene as a biomarker
Nandi, D., Cheema, P. S., Jaiswal, N., & Nag, A. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.08.009 · Cited by 151
Activation of AMPK inhibits cervical cancer cell growth through AKT/FOXO3a/FOXM1 signaling cascade
Yung, M. M. H., Chan, D. W., Liu, V. W. S., Yao, K., & Ngan, H. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-327 · Cited by 112
“impairs tumor growth of this cancer in vitro and in vivo [18,25,27,33], suggesting that targeting FOXM1 is an appealing and potential approach for anticancer therapeutics.”
BackgroundSelf-citationFOXM1: A Multifunctional Oncoprotein and Emerging Therapeutic Target in Ovarian Cancer
Liu, C., Barger, C. J., & Karpf, A. R. (2021) · Cancers · doi:10.3390/cancers13123065 · Cited by 114
“Growth factor receptor-bound protein 7 (GRB7), which is a signal transducing adaptor protein that is overexpressed in ovarian cancer, promotes constitutive activation of the MAPK/ERK pathway and thereby leads to enhanced FOXM1 activity [205].”
BackgroundZhao, F., Siu, M. K. Y., Jiang, L., Tam, K. F., Ngan, H. Y. S., Le, X. F., Wong, O. G. W., Wong, E. S. Y., Gomes, A. R., Bella, L., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0113478 · Cited by 88
“Although FOXM1’s association with high grade ovarian carcinomas has been reported [16], whether FOXM1 participates in the acquisition of paclitaxel resistance remains undefined.”
BackgroundSelf-citationChen, K., Liu, M. X., Mak, C. S. L., Yung, M. M. H., Leung, T. H., Xu, D., Ngu, S., Chan, K. K. L., Yang, H., Ngan, H., et al. (2017) · Theranostics · doi:10.7150/thno.22377 · Cited by 86
“GRB7 gene amplification has been documented in numerous human cancers, such as testicular neoplasms, esophageal squamous cell carcinoma (ESCC), breast and ovarian cancers [20, 27-29].”
Self-citationChu, P.-Y., Tai, Y.-L., & Shen, T.-L. (2019) · Cells · doi:10.3390/cells8050435 · Cited by 84
“Consistently, inhibition of the specific kinase activity of Grb7-mediated downstream signals significantly reduces Grb7-mediated cancer invasion [59].”
BackgroundInfluentialYu, C., Luo, D., Yu, J., Zhang, M., Zheng, X., Xu, G., Wang, J., Wang, H., Xu, Y., Jiang, K., et al. (2022) · Oncogene · doi:10.1038/s41388-021-02077-w · Cited by 70
“GRB7 targeting inhibits ovarian cancer tumor growth through the ERK inhibition [36].”
BackgroundTassi, R. A., Todeschini, P., Siegel, E. R., Calza, S., Cappella, P., Ardighieri, L., Cadei, M., Bugatti, M., Romani, C., Bandiera, E., et al. (2017) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-017-0536-y · Cited by 67
“Despite the unexpected findings of invasion assay, we assessed by RT-qPCR that some FOXM1 downstream targets involved in metastasis, cancer progression, and cisplatin resistance, such as MMP2 [19] and MACC1 [48 – 50], were specifically down-regulated in OSPC2 cells after FOXM1 silencing.”
Chan, D. W., Hui, W. W. Y., Wang, J., Yung, M. M. H., Hui, L. M. N., Qin, Y., Liang, R. R., Leung, T. H. Y., Xu, D., Chan, K., et al. (2016) · Oncogene · doi:10.1038/onc.2016.307 · Cited by 56
Self-citationNath, S., Pigula, M. L., Khan, A. P., Hanna, W., Ruhi, M. K., Dehkordy, F. M., Pushpavanam, K., Rege, K., Moore, K., Tsujita, Y., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9040924 · Cited by 57
Fan, G., Lin, G., Lucito, R., & Tonks, N. K. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.482737 · Cited by 54
“MET (4), the Hedgehog signaling pathway (5), mammalian target of rapamycin (6), andGRB7/ERK (7) as potential avenues for therapeutic intervention.”
BackgroundWang, J., Ju, B., Pan, C.-J., Gu, Y., Li, M., Sun, L., Xu, Y., & Yin, L.-R. (2017) · PubMed · Cited by 50
Bailly, C. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174661 · Cited by 52
Yung, M. M. H., Ross, F. A., Hardie, D. G., Leung, T. H. Y., Zhan, J., Ngan, H., & Chan, D. W. (2015) · Integrative Cancer Therapies · doi:10.1177/1534735415611747 · Cited by 50
Self-citationRetractedCai, P. C. H., Shi, L., Liu, V. W. S., Tang, H. W., Liu, I. J., Leung, T. H. Y., Chan, K. K. L., Yam, J. W. P., Yao, K., Ngan, H., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2273 · Cited by 49
“The immunoreactivity score for each case was calculated as previously protocol [49].”
MethodSelf-citationNameki, R. A., Chang, H. S. Y., Reddy, J., Corona, R. I., & Lawrenson, K. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107722 · Cited by 53
Fan, Q., Cai, Q., & Xu, Y. (2015) · Oncotarget · doi:10.18632/oncotarget.4280 · Cited by 48
Raghuwanshi, S., & Gartel, A. L. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.189015 · Cited by 48
JIN, H., Park, M. H., & Kim, S. M. (2015) · Oncology Reports · doi:10.3892/or.2015.3758 · Cited by 38
“In addition, suppression of FOXM1 by genetic or pharmaceutical approaches significantly inhibited the proliferation and migration of cancers in in vitro and in vivo studies (41-44).”
BackgroundSignal Diversity of Receptor for Advanced Glycation End Products.
Sakaguchi, M., Kinoshita, R., Putranto, E. W., Ruma, I. M. W., Sumardika, I. W., Chen, Y., Tomonobu, N., Yamamoto, K., & Murata, H. (2017) · PubMed · doi:10.18926/amo/55582 · Cited by 39
“tion via activation of the Ras-ERK1/2 pathway [27 , 28].”
MethodCunniff, B., Newick, K., Nelson, K. J., Wozniak, A. N., Beuschel, S. L., Leavitt, B. J., Bhave, A. D., Butnor, K. J., Koenig, A., Chouchani, E. T., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0127310 · Cited by 37
Sphingosine 1-phosphate: A Potential Molecular Target for Ovarian Cancer Therapy?
Dai, L., Xia, P., & Di, W. J. (2014) · Cancer Investigation · doi:10.3109/07357907.2013.876646 · Cited by 33
“by S1P in ovarian cancer cells (42), has long been recognized as a mitogenic factor in promoting the proliferation of this cancer (56, 57).”
BackgroundMa, Y., Xu, Y., & Li, L. (2018) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2018.6575 · Cited by 26
“In another study, Chan et al (40) demonstrated that therapies targeting the ERK signaling pathway reduce the aggressiveness of ovarian cancer cells.”
Kang, K., Choi, Y., Kim, H. H., Yoo, K. H., & Yu, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176141 · Cited by 27
Overexpression of FOXM1 is associated with metastases of nasopharyngeal carcinoma
Jiang, L., Wang, P., & Chen, H. (2014) · Upsala Journal of Medical Sciences · doi:10.3109/03009734.2014.960053 · Cited by 25
“Moreover, during recent years it has been shown that overexpression of FOXM1 increases the invasion and migration potential of pancreatic and ovarian cancer cells in vitro (30,31).”
BackgroundLi, L., Fan, B., Zhang, L.-H., Xing, X., Cheng, X., Wang, X., Guo, T., Du, H., Wen, X., & Ji, J. (2016) · Tumor Biology · doi:10.1007/s13277-016-4816-5 · Cited by 24
Brückner, L., Reinshagen, A., Hoang, N. A., Höhn, A. K., Lordick, F., Bechmann, I., Aktas, B., Nel, I., & Kallendrusch, S. (2021) · Cancers · doi:10.3390/cancers13050956 · Cited by 25
“Thiostrepton treatment downregulated FOXM1 expression on mRNA level in ovarian tissue cultures, confirming results of cell culture experiments [16,17].”
ResultThe role of thyrostimulin and its potential clinical significance
Karponis, D., & Ananth, S. (2017) · Endocrine Regulations · doi:10.1515/enr-2017-0012 · Cited by 23
Targeted Therapy in Ovarian Cancer. A Comprehensive Systematic Review of Literature
Diab, Y. M. S. K., & Muallem, M. Z. (2017) · Anticancer Research · doi:10.21873/anticanres.11631 · Cited by 23
In silico investigation of FOXM1 binding and novel inhibitors in epithelial ovarian cancer
Chen, Y., Ruben, E. A., Rajadas, J., & Teng, N. N. H. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.06.002 · Cited by 23
Sengupta, A., Rahman, M. H., Mateo‐Lozano, S., Tirado, Ò. M., & Notario, V. (2013) · International Journal of Oncology · doi:10.3892/ijo.2013.2016 · Cited by 24
“on EWS cells and tumors at concentrations lower than those reported to be required for effective antitumor activity on other cancer types (44,45,48,49).”
BackgroundTargeting the Calmodulin-Regulated ErbB/Grb7 Signaling Axis in Cancer Therapy
Villalobo, A., García‐Palmero, I., Stateva, S. R., & Jellali, K. (2013) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j3v59v · Cited by 23
“ovarian tumor cells, as demonstrated in vitro and in vivo (131).”
Wang, G., Wu, Y., Su, Y., Qu, N., Chen, B. Z., Zhou, D., Yuan, L., Yin, M., Liu, M., & Zhou, W. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05536-6 · Cited by 22
“The migration and invasion of SK-BR-3 and MDA-MB-453 cells was assessed by J wound healing assays, K transwell assays after transfected with GRB7 or GRB7 plasmid and FLI-06 (10 GRB7-mediated downstream signaling by specific kinase activity abrogates GRB7-mediated cancer migration [42].”
MethodSelf-citationZhao, H., Zhang, X., Jia, X., & Wang, H.-B. (2017) · Pathology - Research and Practice · doi:10.1016/j.prp.2017.05.013 · Cited by 18
Xu, Q., Liu, Z., Zhu, Z., Fan, Y., Chen, R., Xie, X.-H., & Cheng, M. (2021) · Bioengineered · doi:10.1080/21655979.2021.2005225 · Cited by 16
“A study using clinical samples suggested that the GRB7/extracellular signal-regulated kinases (ERK)/forkhead box M1 (FOXM1) signaling cascade is a promising molecular therapeutic target for ovarian cancer [18].”
BackgroundPei, Y., Ran, J., Wen, L., Liu, X., Li, X., Liu, W., & Wei, F. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1054976 · Cited by 13
“revealed that targeting GRB7/ERK/FOXM1 signaling pathway impairs aggressiveness of ovarian cancer cells (29).”
BackgroundTang, H., Yang, P., Yang, X., Peng, S., Hu, X., & Bao, G. (2020) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-020-03798-4 · Cited by 13
Lee, D. W., Lee, W., Kwon, M., & Lee, H. N. (2020) · Oncology Reports · doi:10.3892/or.2020.7845 · Cited by 13
Alcalde, J., González-Muñoz, M., & Villalobo, A. (2020) · Heliyon · doi:10.1016/j.heliyon.2020.e03922 · Cited by 13
“Grb7 has been considered a potential target for anti-tumor therapy [25, 26].”
Sang, J., Kulkarni, K., Watson, G. M., Ma, X., Craik, D. J., Henriques, S. T., Poth, A. G., Benfield, A. H., & Wilce, J. A. (2019) · Molecules · doi:10.3390/molecules24203739 · Cited by 12
Vermehren‐Schmaedick, A., Mhawech-Fauceglia, P. Y., Park, B. S., Pejovic, T. B., & Luoh, S. (2020) · Oncotarget · doi:10.18632/oncotarget.27593 · Cited by 11
“It has been previously shown that GRB7 expression is associated with high-grade ovarian cancer [23], but the correlation between GRB7 overexpression and clinical outcome is not known.”
BackgroundKorkmaz, F. D., Doğan, İ., Esendağlı, G., & Ekmekçi, A. (2022) · Molecular Biology Reports · doi:10.1007/s11033-022-07751-0 · Cited by 10
Chen, X., Han, Q., Song, J., & Pu, Y. (2024) · Medicine · doi:10.1097/md.0000000000040608 · Cited by 7
Dual‐targeting therapy against HER3 / MET in human colorectal cancers
Yamasaki, A., Miyake, R., Hara, Y., Okuno, H., Imaida, T., Okita, K., Okazaki, S., Akiyama, Y., Hirotani, K., Endo, Y., et al. (2023) · Cancer Medicine · doi:10.1002/cam4.5673 · Cited by 7
Grb7 gene amplification and protein expression by FISH and IHC in ovarian cancer.
Zeng, M., Yang, Z., Hu, X., Liu, Y., Yang, X., Ran, H., Li, Y., Xu, L., & Yu, Q. (2015) · PubMed · Cited by 6
GPR19 Drives Cell Cycle Progression via ERK-Dependent FOXM1 Activation in p53-Mutant Breast Cancer
Qiu, J., Tian, C., Li, H., Gao, S., Yang, C., Luo, Q., Liu, Y., He, K., Li, K., Peng, Y., et al. (2026) · Frontiers in Bioscience-Landmark · doi:10.31083/fbl52064 · Cited by 2
Hasani, N. A. H., NMMNM, R., Mr, I., Sheikh Abdul Kadir, S. H., & Amin, I. M. (2016) · Journal of Health and Translational Medicine · doi:10.22452/jummec.vol19no1.2 · Cited by 1
Staff, T. P. O. (2014) · PLoS ONE · doi:10.1371/journal.pone.0110304
Morzyglod, L. (2015) · theses.fr (ABES) · doi:10.70675/753e089bzb365z4663za465z80005940e75b
Metadata
- Authors
- Chan, D. W., Hui, W. W. Y., Cai, P. C. H., Liu, M. X., Yung, M. M. H., Mak, C. S. L., Leung, T. H. Y., Chan, K. K. L., & Ngan, H. Y. S.
- Affiliations
- University of Hong Kong (HK)
- Corresponding author
- Chan, David W.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-12-20
- Volume
- 7
- Issue
- 12
- Pages
- e52578
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3527599
- OpenAlex
- W2000095065
- Cited by
- 51
- References
- 50
- Citations by year
- 2026: 1 · 2024: 2 · 2023: 3 · 2022: 1 · 2021: 6 · 2020: 7 · 2019: 2 · 2018: 1 · 2017: 8 · 2016: 3 · 2015: 6 · 2014: 5 · 2013: 6
- FWCI
- 6.35
- Type
- journal article
- Language
- en
- Update notices
- correction (2014-10-06)
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- The HKU Scholars Hub (University of Hong Kong) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Keywords
- ovarian cancer, Grb7, ERK1/2 phosphorylation, FOXM1, tumor aggressiveness, tumor grade, cell migration and invasion, tumor growth, ERK inhibition, thiostrepton, U0126, PD98059, molecular therapy
- MeSH terms
- Forkhead Box Protein M1, Animals, Cell Movement, Female, Humans, Mice, Inbred BALB C, Neoplasm Invasiveness, Ovarian Neoplasms, Phosphorylation, Signal Transduction, Xenograft Model Antitumor Assays, Cell Line, Tumor, Extracellular Signal-Regulated MAP Kinases, Cell Proliferation, Mice, GRB7 Adaptor Protein, Forkhead Transcription Factors, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.